OBJECTIVES: Treatment of patients with haemophilia, a congenital bleeding disorder, treated with repeated infusions of clotting factor concentrates, requires a substantial amount of economical and human resources and therefore it is mandatory to investigate treatment satisfaction of haemophilic patients. Purpose of this study was to evaluate patients' experience of different treatment regimens and to validate the newly developed haemophilia-specific treatment satisfaction scale for adults (Hemo-SatA) in the COCHE Study (Cost of Care of Hemophilia Study). METHODS: 233 adult haemophilia patients without inhibitors from 23 Italian Haemophilia Centers were enrolled in the naturalistic, multicenter, longitudinal COCHE Study. Treatment satisfaction was assessed with the Hemo-SatA, which consists of 34 items pertaining to 6 domains (ease & convenience, efficacy, burden, specialist, centre, general). RESULTS: Mean age of patients was 37 years. Around one-third of the patients received prophylactic treatment (n=75) and most of them were treated with recombinant products (58.8%). In general patients were satisfied with their treatment. Patients were mostly unsatisfied in the dimensions “ease & convenience” and “efficacy”; 42% worried about the risk of inhibitors associated with their medication and 14% were unsatisfied with the number of infusions that are needed to stop a bleeding. Significant differences in treatment satisfaction (Hemo-SatA) were found for socio-demographic data concerning marital status and age groups (“burden”); separated persons were more unsatisfied with their treatment (“specialist”, “general satisfaction”, “Total Hemo-Sat“).Significant differences were found as well for clinical data concerning ‘treatment type', ‘type of haemophilia' and ‘target joints'; patients with more than 1 target joint were more unsatisfied (“efficacy”). Psychometric characteristics of the pilot testing of the Hemo-SatA could be confirmed in the COCHE Study. CONCLUSIONS: Results could confirm that treatment satisfaction is an important outcome criterion in the treatment of patients with chronic diseases. Hemo-SatA proved to be a valid and reliable instrument assessing.